心力衰竭患者N末端B型利钠肽原变化的预后意义
在PARADIGM-HF试验中,2080例射血分数降低的心力衰竭患者基线测定了NT-proBNP,其中1292例基线值>1000 pg/ml者于1个月和8个月复查。NT-proBNP降至≤1000 pg/ml者主要终点风险降低59%;沙库巴曲/缬沙坦组降至≤1000 pg/ml的比例为31%,依那普利组为17%。
要点
- NT-proBNP降至≤1000 pg/ml者主要终点风险较未降至者低59%。
- 沙库巴曲/缬沙坦组31%降至≤1000 pg/ml,依那普利组17%。
- NT-proBNP变化与主要终点风险的关系不因治疗分组而显著交互。
核心结论
- NT-proBNP显著降低的患者后续心血管死亡或心衰住院率较低,且不依赖于治疗分组。
- 沙库巴曲/缬沙坦使NT-proBNP降至≤1000 pg/ml的可能性约为依那普利的近两倍。
研究设计与样本
- PARADIGM-HF试验中,2080例患者测定了基线NT-proBNP,其中1292例基线值>1000 pg/ml者在1个月和8个月时复查。
- 研究分析NT-proBNP变化与结局的关系,并比较沙库巴曲/缬沙坦与依那普利对NT-proBNP的影响。
主要发现
- 随机化1个月后,基线NT-proBNP>1000 pg/ml者中24%降至≤1000 pg/ml。
- NT-proBNP降至≤1000 pg/ml者主要终点风险较未降至者低59%。
- 沙库巴曲/缬沙坦组随机化1个月后NT-proBNP中位数显著低于依那普利组。
- 沙库巴曲/缬沙坦组31%降至≤1000 pg/ml,依那普利组17%。
- 治疗与NT-proBNP变化和主要终点后续风险的关系之间无显著交互作用。
关键数值与推荐
- 基线NT-proBNP>1000 pg/ml者中,1个月后24%降至≤1000 pg/ml。
- NT-proBNP降至≤1000 pg/ml者主要终点风险降低59%。
- 沙库巴曲/缬沙坦组31%降至≤1000 pg/ml,依那普利组17%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Natriuretic peptides (NP) have prognostic value in heart failure (HF), although the clinical importance of changes in NP from baseline is unclear. OBJECTIVES: The authors assessed whether a reduction in N-terminal pro-B-type NP (NT-proBNP) was associated with a decrease in HF hospitalization and cardiovascular mortality (primary endpoint) in patients with HF and reduced ejection fraction, whether treatment with sacubitril/valsartan reduced NT-proBNP below specific partition values more than enalapril, and whether the relationship between changes in NT-proBNP and changes in the primary endpoint were dependent on assigned treatment. METHODS: In PARADIGM-HF (Prospective Comparison of ARNI [Angiotensin Receptor-Neprilysin Inhibitor] with ACEI [Angiotensin-Converting-Enzyme Inhibitor] to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial), baseline NT-proBNP was measured in 2,080 patients; 1,292 had baseline values >1,000 pg/ml and were reassessed at 1 and 8 months. We related change in NT-proBNP to outcomes. RESULTS: One month after randomization, 24% of the baseline NT-proBNP levels >1,000 pg/ml had fallen to ≤1,000 pg/ml. Risk of the primary endpoint was 59% lower in patients with a fall in NT-proBNP to ≤1,000 pg/ml than in those without such a fall. In sacubitril/valsartan-treated patients, median NT-proBNP was significantly lower 1 month after randomization than in enalapril-treated patients, and it fell to ≤1,000 pg/ml in 31% versus 17% of patients treated with sacubitril/valsartan and enalapril, respectively. There was no significant interaction between treatment and the relationship between change in NT-proBNP and the subsequent risk of the primary endpoint. CONCLUSIONS: Patients who attained a significant reduction in NT-proBNP had a lower subsequent rate of cardiovascular death or HF hospitalization independent of the treatment group. Treatment with sacubitril/valsartan was nearly twice as likely as enalapril to reduce NT-proBNP to values ≤1,000 pg/ml. (Prospective Comparison of ARNI [Angiotensin Receptor-Neprilysin Inhibitor] with ACEI [Angiotensin-Converting-Enzyme Inhibitor] to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial) [PARADIGM-HF]; NCT01035255.).
引用
- Zile MR, Claggett BL, Prescott MF, et al. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure. J Am Coll Cardiol. 2016. PMID: 27908347. doi:10.1016/j.jacc.2016.09.931
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。